scholarly journals Antimicrobial Peptide Resistance Mechanisms of Gram-Positive Bacteria

Antibiotics ◽  
2014 ◽  
Vol 3 (4) ◽  
pp. 461-492 ◽  
Author(s):  
Kathryn Nawrocki ◽  
Emily Crispell ◽  
Shonna McBride
2020 ◽  
Vol 11 ◽  
Author(s):  
Lucas Assoni ◽  
Barbara Milani ◽  
Marianna Ribeiro Carvalho ◽  
Lucas Natanael Nepomuceno ◽  
Natalha Tedeschi Waz ◽  
...  

2014 ◽  
Vol 86 (3) ◽  
pp. 1693-1700 ◽  
Author(s):  
Hashem Etayash ◽  
Keren Jiang ◽  
Thomas Thundat ◽  
Kamaljit Kaur

2021 ◽  
Vol 8 ◽  
Author(s):  
Qun Wang ◽  
Bo Peng ◽  
Mingyue Song ◽  
Abdullah ◽  
Jun Li ◽  
...  

Previous studies from our lab have shown that the antimicrobial peptide F1 obtained from the milk fermentation by Lactobacillus paracasei FX-6 derived from Tibetan kefir was different from common antimicrobial peptides; specifically, F1 simultaneously inhibited the growth of Gram-negative and Gram-positive bacteria. Here, we present follow-on work demonstrating that after the antimicrobial peptide F1 acts on either Escherichia coli ATCC 25922 (E. coli) or Staphylococcus aureus ATCC 63589 (S. aureus), their respective bacterial membranes were severely deformed. This deformation allowed leakage of potassium and magnesium ions from the bacterial membrane. The interaction between the antimicrobial peptide F1 and the bacterial membrane was further explored by artificially simulating the bacterial phospholipid membranes and then extracting them. The study results indicated that after the antimicrobial peptide F1 interacted with the bacterial membranes caused significant calcein leakage that had been simulated by different liposomes. Furthermore, transmission electron microscopy observations revealed that the phospholipid membrane structure was destroyed and the liposomes presented aggregation and precipitation. Quartz Crystal Microbalance with Dissipation (QCM-D) results showed that the antimicrobial peptide F1 significantly reduced the quality of liposome membrane and increased their viscoelasticity. Based on the study's findings, the phospholipid membrane particle size was significantly increased, indicating that the antimicrobial peptide F1 had a direct effect on the phospholipid membrane. Conclusively, the antimicrobial peptide F1 destroyed the membrane structure of both Gram-negative and Gram-positive bacteria by destroying the shared components of their respective phospholipid membranes which resulted in leakage of cell contents and subsequently cell death.


2014 ◽  
Vol 30 ◽  
pp. e86-e87
Author(s):  
X. Chen ◽  
H. Hirt ◽  
Y. Li ◽  
S.-U. Gorr ◽  
C. Aparicio

2015 ◽  
Vol 59 (11) ◽  
pp. 7044-7053 ◽  
Author(s):  
Laura Honeyman ◽  
Mohamed Ismail ◽  
Mark L. Nelson ◽  
Beena Bhatia ◽  
Todd E. Bowser ◽  
...  

ABSTRACTA series of novel tetracycline derivatives were synthesized with the goal of creating new antibiotics that would be unaffected by the known tetracycline resistance mechanisms. New C-9-position derivatives of minocycline (the aminomethylcyclines [AMCs]) were tested forin vitroactivity against Gram-positive strains containing known tetracycline resistance mechanisms of ribosomal protection (Tet M inStaphylococcus aureus,Enterococcus faecalis, andStreptococcus pneumoniae) and efflux (Tet K inS. aureusand Tet L inE. faecalis). A number of aminomethylcyclines with potentin vitroactivity (MIC range of ≤0.06 to 2.0 μg/ml) were identified. These novel tetracyclines were more active against one or more of the resistant strains than the reference antibiotics tested (MIC range, 16 to 64 μg/ml). The AMC derivatives were active against bacteria resistant to tetracycline by both efflux and ribosomal protection mechanisms. This study identified the AMCs as a novel class of antibiotics evolved from tetracycline that exhibit potent activityin vitroagainst tetracycline-resistant Gram-positive bacteria, including pathogenic strains of methicillin-resistantS. aureus(MRSA) and vancomycin-resistant enterococci (VRE). One derivative, 9-neopentylaminomethylminocycline (generic name omadacycline), was identified and is currently in human trials for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).


2014 ◽  
Vol 6 (2) ◽  
pp. 1131-1138 ◽  
Author(s):  
Hashem Etayash ◽  
Lana Norman ◽  
Thomas Thundat ◽  
Michael Stiles ◽  
Kamaljit Kaur

Sign in / Sign up

Export Citation Format

Share Document